GMAB - Genmab up 1.3% reports DARZALEX Q2 worldwide sales
2023-07-20 07:37:43 ET
- Genmab ( GMAB ) said that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous product as reported by Johnson & Johnson were $2,431M in Q2 2023.
- Net trade sales were $1,322M in the U.S. and $1,110M in the rest of the world.
- Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.
- The stock price is up 1.3% pre-market on Thursday.
For further details see:
Genmab up 1.3%, reports DARZALEX Q2 worldwide sales